NEWS

CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2025/26 Canadian influenza season, based on the trivalent strains recommended by the World Health Organization (WHO), which is supported by the National Advisory Committee on Immunization (NACI).1,2

CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.

CSL Seqirus, a business of CSL (ASX: CSL), announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health.

FLUAD® Influenza vaccine (surface antigen, inactivated, adjuvanted with MF59®) is now preferentially recommended by the Comité sur l’immunisation du Québec (Quebec Immunization Committee, or CIQ) for adults 65 years of age and older.

· CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.
· Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and livestock have been reported in the U.S.
· Fourth avian influenza pandemic preparedness award to CSL Seqirus under a multi-year agreement with Biomedical Advanced Research and Development Authority (BARDA).